Categories
Archives
- 2026
- 2025
- 2024
- 2023
- 2022
- 2021
Mar
09
First Presentation of Year 4 BIMZELX® (bimekizumab-bkzx) Data Showed Long-Term Maintenance of Complete Skin Clearance in Moderate-to-Severe Plaque Psoriasis
Mar
08
BIMZELX® 48-Week Phase 3 Analyses in Moderate-to-Severe Hidradenitis Suppurativa Showed Sustained Improvements in Skin Pain and Draining Tunnel Count
Jan
11
Our Wish in 2024: Renewed Hope for People Living with Chronic Inflammatory Diseases
Oct
18
BIMZELX® Approved by the U.S. FDA for the Treatment of Adults with Moderate-to-Severe Plaque Psoriasis
Mar
26
New Long-Term Complete Skin Clearance Data for Bimekizumab in Moderate to Severe Plaque Psoriasis Presented at the 2022 AAD Annual Meeting
Dec
16
Positive Top-Line Results for Bimekizumab in Phase 3 Ankylosing Spondylitis Trial
Oct
22
UCB Presents Number Needed to Treat Analysis for Bimekizumab in Moderate to Severe Plaque Psoriasis at AMCP Nexus
Oct
16
Update on U.S. FDA Review of Biologics License Application (BLA) for bimekizumab
Sep
29
New Bimekizumab Two-Year Data in Moderate to Severe Plaque Psoriasis Presented at the 30th European Academy of Dermatology and Venereology Congress
